Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8322153 | 0.82 | TRPA1 (0.52) | MAPTLMNAKDM4EHTTTRPA1 | |
| SCHEMBL11352142 | 0.77 | MAPT (0.53) | MAPTLMNAKDM4EHTTTRPA1 | |
| SCHEMBL29951782 | 0.77 | ERN1 (0.58) | MAPTLMNAKDM4EHTTTRPA1 | |
| SCHEMBL13759274 | 0.77 | MAPT (0.53) | MAPTLMNAKDM4EHTTTRPA1 | |
| SCHEMBL172664 | 0.77 | ERN1 (0.58) | MAPTLMNAKDM4EHTTTRPA1 | |
| SCHEMBL8879774 | 0.76 | ALOX5 (0.52) | MAPTLMNAKDM4ETP53TDP1 | |
| SCHEMBL11407468 | 0.76 | ERN1 (0.56) | MAPTLMNAKDM4EHTTTRPA1 | |
| SCHEMBL1109599 | 0.76 | MAPT (0.52) | MAPTLMNAKDM4EHTTTRPA1 | |
| SCHEMBL8958284 | 0.76 | ERN1 (0.56) | MAPTLMNAKDM4EHTTTRPA1 | |
| SCHEMBL8829593 | 0.76 | MAPT (0.52) | MAPTLMNAKDM4EHTTTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138411-B2 | Substituted benzopyran derivatives for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7109211-B2 | Substituted benzopyran derivatives for the treatment of inflammation | PHARMACIA CORPORATION (OF PFIZER, INC.) (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050049252-A1 | Substituted benzopyran derivatives for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2005-03-03 | — | — | US | disclosed |
| US-6806288-B1 | CYCLOOXYGENASE-2 MEDIATED DISORDERS; REDUCES INFLAMMATION; FEWER SIDE EFFECTS | G.D. SEARLE & CO. | 2004-10-19 | — | — | US | disclosed |
| US-20040127539-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040038977-A1 | Substituted bezopyran derivatives for the treatment of inflammation | G.D. SEARLE & CO. | 2004-02-26 | — | — | US | disclosed |
| EP-0977748-B1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6492390-B2 | TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS. | G.D. SEARLE & CO. | 2002-12-10 | — | — | US | disclosed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2000023433-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-04-27 | — | — | WO | disclosed |
| US-6034256-A | CYCLOOXYGEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0977748-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | disclosed |
| US-5994353-A | ANTIARTHRITIC AGENTS; ANALGESICS; ANTIINFLAMMATORY AGENTS | ZENECA LIMITED (GB) | 1999-11-30 | — | — | US | disclosed |
| WO-1998047890-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-10-29 | — | — | WO | disclosed |
| EP-0835246-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997000863-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1997-01-09 | — | — | WO | disclosed |
| EP-0167371-B1 | DIHYDROPYRIDINE COMPOUNDS, THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-03-06 | — | — | EP | disclosed |
| US-4727082-A | CARDIOVASCULAR DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-02-23 | — | — | US | disclosed |
| EP-0167371-A2 | Dihydropyridine compounds, their production, and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1986-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038977-A1 | Substituted bezopyran derivatives for the treatment of inflammation | PTGS1, PTGES2, IL1R1 | MAPT 3750/4885LMNA 2994/4885KDM4E 2392/4885 |
| US-20050049252-A1 | Substituted benzopyran derivatives for the treatment of inflammation | PTGES2, PTGS2, PTGER2 | MAPT 4203/4885LMNA 2202/4885KDM4E 2467/4885 |
| US-20040127539-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | MAPT 4820/4885LMNA 2507/4885KDM4E 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.